Skip to main content
Top

2022 | OriginalPaper | Hoofdstuk

18. Migraine

Auteurs : dr. Marie-Louise Bartelink, prof. dr. Antoinette Maassen van den Brink

Gepubliceerd in: Gendersensitieve huisartsgeneeskunde

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Migraine is een veelvoorkomende chronische vorm van aanvalsgewijze hoofdpijn, die vaak een grote impact heeft op het dagelijks functioneren. Migraine komt vaker voor bij vrouwen dan bij mannen. Het optreden van migraine wordt beïnvloed door de menarche, de menstruatie, zwangerschap, pilgebruik en menopauze. De precieze pathofysiologie en welke geslachtshormonen hierbij betrokken zijn is nog onvoldoende duidelijk, maar oestrogeenschommelingen lijken een rol te spelen. Er is een relatie tussen migraine en hart- en vaatziekten: migraine vormt een onafhankelijke risicofactor voor het optreden van herseninfarct, hersenbloeding en myocardinfarct. De behandeling van migraine wordt stapsgewijs ingezet en bestaat uit analgetica, bij onvoldoende effect gevolgd door aanvalsbehandeling met triptanen. Bij onvoldoende effectiviteit hiervan en frequente aanvallen dient profylactische behandeling overwogen te worden.
Literatuur
2.
go back to reference Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16:76–87.CrossRef Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16:76–87.CrossRef
4.
go back to reference Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17:954–76. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17:954–76.
5.
go back to reference Delaruelle Z, Ivanova TA, Khan S, Negro A, et al. Male and female sex hormones in primary headaches. J Headache Pain. 2018;19:117.CrossRef Delaruelle Z, Ivanova TA, Khan S, Negro A, et al. Male and female sex hormones in primary headaches. J Headache Pain. 2018;19:117.CrossRef
6.
go back to reference Edvinsson L, Villalón CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012;136:319–33.CrossRef Edvinsson L, Villalón CM, MaassenVanDenBrink A. Basic mechanisms of migraine and its acute treatment. Pharmacol Ther. 2012;136:319–33.CrossRef
7.
go back to reference Labastida-Ramírez A, Rubio-Beltrán E, Villalón CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. Cephalalgia. 2019;39:435–44.CrossRef Labastida-Ramírez A, Rubio-Beltrán E, Villalón CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. Cephalalgia. 2019;39:435–44.CrossRef
8.
go back to reference De Boer I, Van den Maagdenberg AMJM, Terwindt GM. Advance in genetics of migraine. Review Curr Opin Neurol. 2019;32:413–21.CrossRef De Boer I, Van den Maagdenberg AMJM, Terwindt GM. Advance in genetics of migraine. Review Curr Opin Neurol. 2019;32:413–21.CrossRef
9.
go back to reference Finocchi C, Sivori G. Food as trigger and aggravating factor of migraine. Neurol Sci. 2012;33Suppl1:S77–80. Finocchi C, Sivori G. Food as trigger and aggravating factor of migraine. Neurol Sci. 2012;33Suppl1:S77–80.
10.
go back to reference Negro A, Delaruelle Z, Ivanova TA, Khan S, et al. Headache and pregnancy: a systematic review. J Headache Pain. 2017;18:106.CrossRef Negro A, Delaruelle Z, Ivanova TA, Khan S, et al. Headache and pregnancy: a systematic review. J Headache Pain. 2017;18:106.CrossRef
11.
go back to reference Gupta S, Mehrotra S, Villalón CM, Perusquía M, Saxena PR, MaassenVanDenBrink A. Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther. 2007;113:321. Gupta S, Mehrotra S, Villalón CM, Perusquía M, Saxena PR, MaassenVanDenBrink A. Potential role of female sex hormones in the pathophysiology of migraine. Pharmacol Ther. 2007;113:321.
12.
go back to reference Van Oosterhout WPJ, Schoonman GG, Van Zwet EW, Dekkers OM, Terwindt GM, MaassenVanDenBrink A, Ferrari MD. Female sex hormones in men with migraine. Neurology. 2018;91:e374–81.CrossRef Van Oosterhout WPJ, Schoonman GG, Van Zwet EW, Dekkers OM, Terwindt GM, MaassenVanDenBrink A, Ferrari MD. Female sex hormones in men with migraine. Neurology. 2018;91:e374–81.CrossRef
13.
go back to reference Van Casteren DS, Kurth T, Danser AHJ, Terwindt GM, MaassenVanDenBrink A. Sex differences in response to triptans: a systematic review and meta-analysis. Neurology. 2021;96:162.CrossRef Van Casteren DS, Kurth T, Danser AHJ, Terwindt GM, MaassenVanDenBrink A. Sex differences in response to triptans: a systematic review and meta-analysis. Neurology. 2021;96:162.CrossRef
14.
go back to reference Rapport AM, Edvinsson L. Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache. Neurol Sci. 2019;40(Suppl 1):S75–80.CrossRef Rapport AM, Edvinsson L. Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache. Neurol Sci. 2019;40(Suppl 1):S75–80.CrossRef
15.
go back to reference De Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211:107528. De Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020;211:107528.
16.
go back to reference MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37:779–88.CrossRef MaassenVanDenBrink A, Meijer J, Villalón CM, Ferrari MD. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37:779–88.CrossRef
17.
go back to reference Aukes AM, Yurtsever FN, Boutin A, Visser MC, De Groot CJM. Associations between migraine and adverse pregnancy outcomes: systematic review and meta-analysis. Obstet Gynecol Surv. 2019;74:738–48.CrossRef Aukes AM, Yurtsever FN, Boutin A, Visser MC, De Groot CJM. Associations between migraine and adverse pregnancy outcomes: systematic review and meta-analysis. Obstet Gynecol Surv. 2019;74:738–48.CrossRef
18.
go back to reference Sacco S, Merki-Feld GS, Lehrmann Ægidius K, et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018;19:76.CrossRef Sacco S, Merki-Feld GS, Lehrmann Ægidius K, et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2018;19:76.CrossRef
19.
go back to reference Nierenburg H, Ailani J, Malloy M, et al. Systematic review of preventive and acute treatment of menstrual migraine. Headache. 2015;55:1052–71.CrossRef Nierenburg H, Ailani J, Malloy M, et al. Systematic review of preventive and acute treatment of menstrual migraine. Headache. 2015;55:1052–71.CrossRef
20.
go back to reference Adelborg K, Komjáthine Szépligeti S, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018;360:k96. Adelborg K, Komjáthine Szépligeti S, Holland-Bill L, et al. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018;360:k96.
21.
go back to reference Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018;8:e020498. Mahmoud AN, Mentias A, Elgendy AY, et al. Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open. 2018;8:e020498.
22.
go back to reference Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610. Kurth T, Winter AC, Eliassen AH, et al. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016;353:i2610.
23.
go back to reference Kurth T, Rist PM, Ridker PM, Kotler G, Bubes V, Buring JE. Association of migraine with aura and other risk factors with incident cardiovascular disease in women. JAMA. 2020;323:2281–9.CrossRef Kurth T, Rist PM, Ridker PM, Kotler G, Bubes V, Buring JE. Association of migraine with aura and other risk factors with incident cardiovascular disease in women. JAMA. 2020;323:2281–9.CrossRef
24.
go back to reference Sacco S, Merki-Feld GS, Lehrmann Ægidius K, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18:108.CrossRef Sacco S, Merki-Feld GS, Lehrmann Ægidius K, et al. Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). J Headache Pain. 2017;18:108.CrossRef
25.
go back to reference Chang CL, Donaghy M, Poulter N; The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study. BMJ. 1999;318:13–8. Chang CL, Donaghy M, Poulter N; The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Migraine and stroke in young women: case-control study. BMJ. 1999;318:13–8.
26.
go back to reference Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35:118–31.CrossRef Roberto G, Raschi E, Piccinni C, et al. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015;35:118–31.CrossRef
Metagegevens
Titel
Migraine
Auteurs
dr. Marie-Louise Bartelink
prof. dr. Antoinette Maassen van den Brink
Copyright
2022
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-368-2707-2_18